Guru Fundamental Report for TMO

Validea's guru fundamental report indicates Thermo Fisher Scientific (TMO) scored 68% using Pim van Vliet's Multi-Factor Investor model, falling below the 80% threshold for 'some interest.' While TMO passed the low volatility and market cap criteria, its neutral performance in momentum and net payout yield contributed to an overall 'FAIL' in the final rank, suggesting it does not align with this quantitative strategy focused on low volatility, strong momentum, and high net payout yields.

Analysis

Thermo Fisher Scientific (TMO) does not currently align with the criteria of the quantitative, multi-factor model developed by Pim van Vliet, according to a Validea fundamental report. The company received a score of 68%, which falls short of the 80% threshold that indicates strategic interest. While TMO, a large-cap medical equipment stock, successfully passed the model's screens for market capitalization and low volatility (Standard Deviation), it registered only a 'Neutral' rating for its 'Twelve Minus One Momentum' and 'Net Payout Yield'. This mixed performance, particularly the lack of strong momentum and high shareholder yield, resulted in an overall 'FAIL' on the strategy's final rank, suggesting that despite its conservative, low-risk profile, TMO lacks the other key factors required by this specific investment approach.

Key Decisions for Investors

• Investors employing quantitative, multi-factor strategies focused on momentum and yield should recognize that TMO currently fails key screens and may not be an optimal holding for such portfolios.
• Conservative or income-focused investors should take note of the 'Neutral' rating on TMO's net payout yield, which suggests its capital return policy is not currently a primary driver of value according to this model.
• While the stock's low-volatility characteristic is confirmed, the neutral momentum signal warrants caution, as it could imply a period of range-bound trading or sluggish price performance in the near term.